Abstract：
BACKGROUND: French guidelines recommend stopping biologic treatment of psoriasis between 3 and 24 weeks before conception in accordance with the relevant Summary of Product Characteristics (SmPC). The aim of this study was to evaluate the real-life practice of dermatologists in the management of pregnant women with psoriasis previously treated with biologic agents. We wished to assess the level of practitioner adherence to the relevant SmPCs.
METHODS: We conducted a study in collaboration with GRPso and Resopso. A computerized questionnaire was completed by the practitioners. We performed descriptive statistics and studied the profile of the practitioners, their level of confidence with continuation of biological agents during pregnancy, and their reported practices on the use of biological agents in pregnancy. Statistical analyses were performed using XLSTAT. A p-value of less than 0.05 was considered significant.
RESULTS: A total of 63 dermatologists (women: 71%; mean age 43.8 years) participated in this study, the majority of whom were hospital-based (87%). Recommendations were followed by 36.5% of practitioners, while 44% reported discontinuing biologic agents on diagnosis of pregnancy, and 20.5% reported using these agents during pregnancy. Among dermatologists with more than ten years of experience, 19% reported following the SmPC. Among dermatologists with a patient base >200 (patients treated with biologic agents for psoriasis), 19% reported following the SmPC compared to 54% of practitioners with less than 50 patients. The mean age of dermatologists following the SmPC was 41 years vs. 47 years for those not following the SmPC.
CONCLUSIONS: The majority of practitioners do not follow recommendations on discontinuation of biologic agents before the planning of pregnancy by patients.
METHODS: We conducted a study in collaboration with GRPso and Resopso. A computerized questionnaire was completed by the practitioners. We performed descriptive statistics and studied the profile of the practitioners, their level of confidence with continuation of biological agents during pregnancy, and their reported practices on the use of biological agents in pregnancy. Statistical analyses were performed using XLSTAT. A p-value of less than 0.05 was considered significant.
RESULTS: A total of 63 dermatologists (women: 71%; mean age 43.8 years) participated in this study, the majority of whom were hospital-based (87%). Recommendations were followed by 36.5% of practitioners, while 44% reported discontinuing biologic agents on diagnosis of pregnancy, and 20.5% reported using these agents during pregnancy. Among dermatologists with more than ten years of experience, 19% reported following the SmPC. Among dermatologists with a patient base >200 (patients treated with biologic agents for psoriasis), 19% reported following the SmPC compared to 54% of practitioners with less than 50 patients. The mean age of dermatologists following the SmPC was 41 years vs. 47 years for those not following the SmPC.
CONCLUSIONS: The majority of practitioners do not follow recommendations on discontinuation of biologic agents before the planning of pregnancy by patients.
摘要：
背景：法国指南建议根据相关产品特征摘要（SmPC），在受孕前3-24周停止银屑病的生物治疗。这项研究的目的是评估皮肤科医生在治疗先前用生物制剂治疗的牛皮癣孕妇中的现实生活实践。我们希望评估从业者对相关SmPC的依从性水平。
方法：我们与GRPso和Resopso合作进行了一项研究。从业人员完成了计算机化的问卷。我们进行了描述性统计，并研究了从业者的概况，他们对怀孕期间继续使用生物制剂的信心水平，以及他们报告的在怀孕期间使用生物制剂的做法。使用XLSTAT进行统计分析。小于0.05的P值被认为是显著的。
结果：共有63名皮肤科医生（女性：71％；平均年龄43.8岁）参加了这项研究，其中大多数是医院(87%)。36.5％的从业人员遵循了建议，而44%的人报告说在诊断妊娠时停止使用生物制剂，20.5%的人报告在怀孕期间使用这些药物。在有十多年经验的皮肤科医生中，19%的人报告在SmPC之后。在患者基础>200的皮肤科医生中（接受牛皮癣生物制剂治疗的患者），19％的人在SmPC之后报告，而54％的从业者少于50名患者。SmPC之后的皮肤科医生的平均年龄是41岁，而不是对于那些不遵循SmPC的人来说，这是47年。
结论：大多数医生在患者计划妊娠前不遵循停用生物制剂的建议。
方法：我们与GRPso和Resopso合作进行了一项研究。从业人员完成了计算机化的问卷。我们进行了描述性统计，并研究了从业者的概况，他们对怀孕期间继续使用生物制剂的信心水平，以及他们报告的在怀孕期间使用生物制剂的做法。使用XLSTAT进行统计分析。小于0.05的P值被认为是显著的。
结果：共有63名皮肤科医生（女性：71％；平均年龄43.8岁）参加了这项研究，其中大多数是医院(87%)。36.5％的从业人员遵循了建议，而44%的人报告说在诊断妊娠时停止使用生物制剂，20.5%的人报告在怀孕期间使用这些药物。在有十多年经验的皮肤科医生中，19%的人报告在SmPC之后。在患者基础>200的皮肤科医生中（接受牛皮癣生物制剂治疗的患者），19％的人在SmPC之后报告，而54％的从业者少于50名患者。SmPC之后的皮肤科医生的平均年龄是41岁，而不是对于那些不遵循SmPC的人来说，这是47年。
结论：大多数医生在患者计划妊娠前不遵循停用生物制剂的建议。
